Rxcurve
HCPCS J9311 · per 10 mg

Inj rituximab, hyaluronidase

Products billed under this code include Rituxan Hycela.

Payment limit per 10 mg, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9311

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Rituxan Hycela Genentech, Inc. 50242-0108-01 140 $5,077.10
Rituxan Hycela Genentech, Inc. 50242-0109-01 160 $5,802.40

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $36.265 −$0.124 10 mg Inj rituximab, hyaluronidase v1, posted September 17, 2026
3Q26 $36.389 +$0.107 10 mg Inj rituximab, hyaluronidase v1, posted September 15, 2026
2Q26 $36.282 −$0.592 10 mg Inj rituximab, hyaluronidase v1, posted September 15, 2026
1Q26 $36.874 +$0.181 10 mg Inj rituximab, hyaluronidase v1, posted September 15, 2026
4Q25 $36.693 −$0.269 10 mg Inj rituximab, hyaluronidase v1, posted September 8, 2026
3Q25 $36.962 −$0.564 10 mg Inj rituximab, hyaluronidase v1, posted March 10, 2026
2Q25 $37.526 +$0.95 10 mg Inj rituximab, hyaluronidase v1, posted March 10, 2026
1Q25 $36.576 −$0.366 10 mg Inj rituximab, hyaluronidase v1, posted December 19, 2025
4Q24 $36.942 +$0.415 10 mg Inj rituximab, hyaluronidase v1, posted June 11, 2025
3Q24 $36.527 −$0.712 10 mg Inj rituximab, hyaluronidase v1, posted June 11, 2025
2Q24 $37.239 −$0.166 10 mg Inj rituximab, hyaluronidase v1, posted March 11, 2025
1Q24 $37.405 +$0.272 10 mg Inj rituximab, hyaluronidase v1, posted December 19, 2024
4Q23 $37.133 −$0.325 10 mg Inj rituximab, hyaluronidase v1, posted October 10, 2024
3Q23 $37.458 −$0.034 10 mg Inj rituximab, hyaluronidase v1, posted June 5, 2024
2Q23 $37.492 +$0.322 10 mg Inj rituximab, hyaluronidase v1, posted February 23, 2024
1Q23 $37.17 −$0.707 10 mg Inj rituximab, hyaluronidase v1, posted December 6, 2023
4Q22 $37.877 −$0.024 10 mg Inj rituximab, hyaluronidase v1, posted June 22, 2023
3Q22 $37.901 −$0.058 10 mg Inj rituximab, hyaluronidase v1, posted June 9, 2023
2Q22 $37.959 −$0.251 10 mg Inj rituximab, hyaluronidase v1, posted December 14, 2022
1Q22 $38.21 +$0.27 10 mg Inj rituximab, hyaluronidase v1, posted June 8, 2022
4Q21 $37.94 −$0.329 10 mg Inj rituximab, hyaluronidase v1, posted June 2, 2022
3Q21 $38.269 −$0.528 10 mg Inj rituximab, hyaluronidase v1, posted June 2, 2022
2Q21 $38.797 −$1.104 10 mg Inj rituximab, hyaluronidase v1, posted March 1, 2022
1Q21 $39.901 – 10 mg Inj rituximab, hyaluronidase v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files